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Abstract
Background: Treatment costs for children with growth hormone (GH) deficiency are subsidized by the government
in Japan if the children meet clinical criteria, including height limits (boys: 156.4 cm; girls: 145.4 cm). However,
several funding programs, such as a subsidy provided by local governments, can be used by those who exceed
the height limits. In this study, we explored the impacts of financial support on GH treatment using this natural
allocation.
Methods: A retrospective analysis of 696 adolescent patients (451 boys and 245 girls) who reached the height
limits was conducted. Associations between financial support and continuing treatment were assessed using
multiple logistic regression analyses adjusting for age, sex, height, growth velocity, bone age, and adverse effects.
Results: Of the 696 children in the analysis, 108 (15.5 %) were still eligible for financial support. The proportion
of children who continued GH treatment was higher among those who were eligible for support than among
those who were not (75.9 % vs. 52.0 %, P < 0.001). The odds ratios of financial support to continuing treatment
were 4.04 (95 % confidence interval [CI]: 1.86–8.78) in boys and 1.72 (95 % CI: 0.80–3.70) in girls, after adjusting for
demographic characteristics and clinical factors.
Conclusions: Financial support affected decisions on treatment continuation for children with GH deficiency.
Geographic variations in eligibility for financial support pose an ethical problem that needs policy attention. An
appropriate balance between public spending on continuation of therapy and improved quality of life derived from
it should be explored.
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Background
Biosynthetic human growth hormone (GH) is very
expensive. The annual cost for one child weighing 30 kg
is reported to be approximately US $15,000 to $24,000
[1–3]. Although most of the costs are covered by public
health insurance or reimbursed by governments in many
countries [4], the extent to which public funding should
be used for support involves ethical issues, resulting in
different policies [1, 4]. Little is known about the impact
of financial support on decision-making for treatment of
children with growth hormone deficiency (GHD).
Important lessons may be learned by studying the case
of Japan, where the level of subsidy for treatment de-
pends purely on the patient’s geographic location (Fig. 1).
Generally, Japan provides universal health insurance
coverage to its citizens up to 70 % of the medical
charges, with the remainder paid by patients [5]. How-
ever, for some rare diseases, including GHD, national
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and local subsidies provide financial support for patients’
out-of-pocket payments. Doctors ensure that patients
understand what programs are available.
The primary program to assist children with GHD is
the Medical Aid Program for Chronic Pediatric Diseases
of Specified Categories (MAPChD) [6, 7]. This program
covers most of the copayments for children with GHD
who meet certain criteria. These criteria include height
limits up to a −2.5 standard deviation score (SDS) of the
height for near-adults (i.e., 17.5-year-old children); spe-
cifically, 156.4 cm for boys and 145.4 cm for girls. An-
other program, established by the national government
in October 2009, is the aid for severe GHD, which
covers treatment costs for patients who exceed the eli-
gible height limits for MAPChD [8]. Local governments
operate two other programs. One is a subsidy offered by
some municipalities for children with mild GHD who do
not meet either of the subsidy criteria defined by the na-
tional government. The other is the generic Child Health
Insurance Subsidy program, which is available in all
1742 municipalities in Japan. This program covers
medical copayments of children who live in these muni-
cipalities, regardless of their health. While the MAPChD
uniformly covers every patient in Japan, the eligibility
criteria and benefits of local programs vary across muni-
cipalities [9]. Some municipalities cover children up to
only 3 years of age, whereas others offer coverage up to
22 years of age. Copayments can range from free to a
few dollars per visit, depending on household income.
Therefore, some children with GHD who exceed the
MAPChD height limit can receive financial support, but
others cannot, depending on where they live.
The present study used this geographic variation in
subsidy access as a natural experiment and examined
the impacts of financial support on GH treatment. Based
on earlier works regarding costs and treatment-seeking
behavior [10–18], we hypothesized that children with
GHD who were eligible for financial support from local
programs were more likely than those who were ineli-
gible for any financial support to continue GH treatment
even after they reached the height limit and were no lon-
ger subsidized by the MAPChD. Insurance coverage
Fig. 1 The proportion of the medical charges paid by insurance, subsidies, and patients’ out-of-pocket payments. GHD, growth hormone defi-
ciency; MAPChD, Medical Aid Program for Chronic Pediatric Diseases of Specified Categories. aHealth insurance covers 70 % of the medical
charges at baseline and provides a monthly cap on family out-of-pocket payment, depending on the annual household income. Because many
GHD patients reach the cap, the combination is expected to result in total coverage of up to about 85 % of total medical expenses among GHD
children, as represented by the oblique line of coverage levels. bThe national aid for severe GHD was established in October 2009. cLocal subsidies
include a local subsidy for mild GHD and the generic Child Health Insurance Subsidy program
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generally has positive effects on the use of pediatric
specialty care in the United States [10–16], but health
economic literature on pediatric care is very limited in
Japan [17, 18]. The aims of the study were to evaluate
the relationship between financial support and patient
behavior among children with GHD and to reveal
possible effects of the geographical variation of local




The study population consisted of children with GHD
registered in the Foundation for Growth Science data-
base [19]. The Foundation for Growth Science works
closely with the government to regulate GH use in
Japan. Until 1997, registration with the foundation was
required to apply for MAPChD, but this requirement
has been discontinued. Currently, clinicians across the
nation voluntarily register patient data in the database,
and the registration rate of children with GHD is esti-
mated to be 30 % [19]. The registry database includes
patient age, sex, clinical data (e.g., height, weight, bone
age, puberty status, results of GH tests, adverse effects),
treatment protocols, whether patients continued or
stopped GH, and the locations of medical institutions.
Registry data included 2471 children who reached the
MAPChD height limits (for boys, 156.4 cm; for girls,
145.4 cm) from January 2001 to May 2013. After exclud-
ing children who did not meet the clinical criteria for
MAPChD eligibility in the first place, we analyzed data
on 696 children (451 boys and 245 girls) who met the
criteria at the first registration and then became
ineligible because they reached the height limits. Criteria
for MAPChD are as follows. The criteria for starting GH
in cases without organic abnormalities are height ≤ −2.5
SDS; insulin-like growth factor1 (IGF-1) < 200 ng/ml or <
150 ng/ml in children < 5 years old; and peak GH in pro-
vocative test ≤ 6 ng/ml. The criteria for starting GH in
cases with organic abnormalities are height ≤ −2.0 SDS or
growth velocity (GV) ≤ −1.5 SDS for 2 years; and peak GH
in provocative test ≤ 3 ng/ml. The criteria for continuing
GH in the first treatment year are GV ≥ 6.0 cm/year or
GV increment ≥ 2.0 cm/year. The criterion for continuing
GH in the second year and after is GV ≥ 3.0 cm/year.
Financial support for patients taller than the MAPChD
height limits
We categorized children who met the criteria for severe
GHD and reached the MAPChD height limit after
October 2009, when the aid for severe GHD was estab-
lished, as those who were eligible for the national sub-
sidy for severe GHD. Criteria for severe GHD included a
peak GH in provocative tests of ≤3 ng/ml in children
with height ≤ −2.0 SDS or a peak GH ≤ 1.8 ng/ml in
adults.
We collected information on the local subsidy pro-
grams for the children in the sample, including the pres-
ence or absence of programs. If a program existed, we
recorded the eligibility criteria either by searching pro-
gram web sites or by contacting the Ministry of Health,
Labour and Welfare, prefectures, and municipalities by
telephone or e-mail. Collating the age of each patient
and the eligibility criteria for the local subsidies in each
municipality, we categorized children into two groups
(eligible and ineligible), depending on whether they were
eligible for at least one of the national or local subsidies.
Data analyses
Statistical comparisons were carried out to compare the
variables between patients who were eligible or ineligible
for financial support, using Student’s t tests, two-group
variance-comparison tests, Welch’s t tests, Wilcoxon’s
rank sum tests, chi-square tests, and Fisher’s exact tests,
according to the type of outcome variables and distribu-
tion of the variables. Multiple logistic regression analysis
was used to assess the relation of financial support to
the continuation of GH treatment, after adjusting for
possible confounders: age in years, sex, height (on a
standard deviation scale; SDS), growth velocity (centime-
ters per year), bone age in years, adverse effects (yes/no),
and when patients reached height limits (before or after
October 2009, when the national subsidy for severe
GHD was implemented). We assessed interaction terms
between sex and financial support and between sex and
bone age to account for possible differences in the ef-
fects of financial support and bone age on the continu-
ation of therapy between boys and girls.
We also conducted sensitivity analyses to test the ro-
bustness of our findings. First, we removed bone age
from the regression model, because 76 values were miss-
ing for bone age and because age and bone age were
moderately correlated (Pearson’s correlation coefficient:
0.53, p < 0.001). Second, we included pubertal status
(pre- or post-puberty) in the regression model. Finally,
to address the possibility that treatment decisions were
changed after the data were registered, we excluded chil-
dren from the treated group if they were not registered
as treated patients in the following year. All analyses
were performed using Stata12-SE (StataCorp LP, College
Station, TX, USA).
Results
Of the 696 children, 42 (6.0 %) were eligible for the na-
tional subsidy for severe GHD. Regarding local subsidies,
medical institutions of the 696 children were distributed
across 155 municipalities (8.9 % of the total 1742 muni-
cipalities in Japan). Of these children, 69 children in 22
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municipalities and three children in two municipalities
were assumed to meet criteria for the local Child Health
Insurance Subsidies and the local subsidy for mild GHD,
respectively. There were six children who were eligible
for both of the national and local subsidies. Overall, 108
children (15.5 %) were categorized as eligible for finan-
cial support after they reached the MAPChD height
limits.
Table 1 lists the characteristics of the children. The
proportion of children who continued GH was higher
among those with financial support than among those
without (75.9 % vs. 52.0 %, p < 0.001, Fig. 2). The
percentage of children who were eligible for financial
support was significantly higher among girls.
As shown in Table 2, multiple logistic regression ana-
lysis revealed that eligibility of financial support was
associated with 4.04 (95 % confidence interval [CI]:
1.86–8.78) times the odds of continuing treatment
among boys, and the corresponding odds among girls
were as small as 1.72 (95 % CI: 0.80–3.70). The percent-
ages of those who continued GH treatment were 76.7 %
among those with financial support and 54.7 % among
those without, after adjusting for the previously men-
tioned factors (80.9 % vs. 52.9 % among boys and 69.4 %
vs. 58.0 % among girls).
Table 3 shows the results of the sensitivity analyses
when we removed bone age from the baseline model,
when we added pubertal status to the model, and when
we excluded the cases in which treatment decisions
might have changed after the data were registered. The
ORs of the first and second analyses are similar to those
in the original model. In the third analysis, 136 patients
were registered to continue GH but were not registered
as being treated in the following year. When we ex-
cluded them as unknown cases, the ORs were 2.91 and
2.37 in boys and girls, respectively.
Discussion
Our findings revealed that 76.7 % of children with GHD
who were financially supported continued treatment
even after they exceeded the government-defined height
criteria, whereas only 54.7 % of those who were not sup-
ported continued GH. Although previous studies have
shown that financial support generally promotes treat-
ment seeking in patients [10–18], this study is the first
to assess the effects of financial support on GH treat-
ment. Importantly, the percentage of children with GHD
who reached the height limit and stopped treatment for
reasons other than financial factors was less than 25 %.
Given the strong impact of public funding on treatment
decisions, the clinical criteria for MAPChD eligibility of
GHD patients must be carefully considered and based
on concrete evidence. Although direct generalization to
other countries may be difficult because of the different
health care systems, our findings can support policy dis-
cussion not only in Japan but also in other countries that
financially support GH treatment [4].
In the present sample, financial support had larger ef-
fects on boys than on girls. Differences in clinical
characteristics (i.e., hormonal levels [20] or treatment re-
sponse [21]) might be possible, although we made ad-
justment for the available clinical factors. Another
possibility is the gender difference in attitudes toward
height. Our data might have reflected patients’ behavior
based on societal preferences for tall males, as shown in
earlier works [22–24]. However, a more likely reason is
Table 1 Characteristics of the 696 patients and additional
financial support after reaching the height limit
Variables Ineligible Eligiblea p
valueb(n = 588) (n = 108)
GH treatment, n (%)
Stopped 282 (48.0) 26 (24.1) <0.001
Continued 306 (52.0) 82 (75.9)
Sex, n (%)
Girls 196 (33.3) 49 (45.4) 0.016
Boys 392 (66.7) 59 (54.6)
Age, y
Mean (SD) 14.8 (1.4) 14.4 (1.3) 0.0015
Girls 13.7 (1.0) 13.7 (1.0) 0.62
Boys 15.4 (1.2) 15.0 (1.1) 0.017
Height SDS
Median −1.59 −1.525 0.16
(Interquartile range) (−1.89 to −1.21) (−1.81 to −1.07)
Growth velocity, cm/y
Mean (SD) 6.7 (2.9) 6.5 (2.5) 0.46
Bone age, y (n = 520) (n = 100)
Mean (SD) 13.1 (1.4) 12.9 (1.2) 0.13
Girls 12.1 (1.1) 12.2 (1.0) 0.82
Boys 13.6 (1.3) 13.6 (0.9) 0.56
Puberty status, n (%) (n = 562) (n = 108)
Pre-puberty 68 (12.1) 17 (15.7) 0.30
Post-puberty 494 (87.9) 91 (84.3)
Adverse effects, n (%)
No 560 (95.2) 105 (97.2) 0.46
Yes 28 (4.8) 3 (2.8)
When patients reached height limit, n (%)
Before October 2009 437 (74.3) 9 (8.3) <0.001
October 2009 and after 151 (25.7) 99 (91.7)
GH growth hormone, SD standard deviation, SDS standard deviation score
aEligible for at least one of the national or local programs of financial support
after the child exceeded the height limit defined by the Medical Aid Program
for Chronic Pediatric Disease of Specified Categories
bChi-square tests, two-tailed t-tests, Wilcoxon rank sum tests, Welch t-tests,
or Fisher’s exact tests
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the age criteria for the local Child Health Insurance Sub-
sidies. Most municipalities provide a subsidy up to
15 years of age, at which point girls typically experience
a natural slowing of growth in height, whereas boys are
still rapidly growing [25]. This fact may have influenced
the girls’ decisions to discontinue therapy. Although we
cannot test this hypothesis because of the limited num-
ber of sample patients in respective municipalities that
had different criteria, consideration of the sex differences
in growth may be needed when setting the criteria for
future subsidies.
Our results are consistent with those of prior studies
describing health care improvement among children
with special health care needs [26] after enrollment in
the State Children’s Health Insurance Program in the
United States [10–15]. Both in specific populations, such
as patients with asthma [12, 13], and in heterogeneous
populations with a wide range of health statuses, such as
children with special health care needs [11, 14, 15], a
decline in unmet health care needs and an increase in
utilization were observed. A study using data from the
RAND Health Insurance Experiment [16] showed a
36 % decline in outpatient episodes for chronic care
among children assigned to cost-sharing plans, com-
pared with those on a free care plan.
The present findings also agree with previous research
in Japan, although the few available studies were re-
stricted to general care. These studies showed that local
subsidy programs directed parental attitudes toward im-
mediate visit [17] and increased the probability of receiv-
ing treatment, especially among children aged between 7
and 12 years [18]. With regard to specialty care for chil-
dren with rare diseases, the current study was the first
to describe the association between local subsidy
programs and care-seeking behavior. Although little at-
tention has been paid to geographical differences in fi-
nancial support in Japan, we found that 22 % more
patients stopped treatment because of a lack of financial
support compared with patients that had financial sup-
port. This geography-based inequality raises an ethical
concern. Currently, MAPChD [6, 7] supports out-of-
pocket payment of children with 704 chronic diseases
[27] and defines subsidy criteria for some of the diseases,
such as GHD. In view of the previous results that paren-
tal attitudes toward severe symptoms of colds were not
significantly different regardless of the level of subsidies
[17], caution should be taken in applying the present re-
sults to other disease that have different clinical features
and payment amounts. However, this study provides
policy-makers with an important reference to resolve
this geographic gap.
Establishing evidence-based criteria for public funding
in GH treatment is an area for future research. The
current height limit does not seem to meet patients’
needs. The mean height velocity of the present popula-
tion was 6.7 cm/year, and the mean bone ages were 13.6
and 12.1 years old in boys and girls, respectively. Ac-
cording to the longitudinal data of Japanese school chil-
dren [25], most children in the present sample were at
peak height velocity and could grow closer to normal
heights. However, a previous cohort study showed that
patients who stopped treatment early spontaneously
gained 0.4 SDS after the end of treatment, possibly be-
cause of the difficulty in distinguishing GHD from pu-
bertal delay [28]. Determining endpoints of treatment is
difficult in the majority of patients without severe GHD
[1]. Treatment appears to be effective [2, 29, 30] and safe
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Fig. 2 The proportion of patients who continued treatment, by financial support status and by sex: a present sample; b boys; c girls
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adult height would provide more information about the
extent to which the public should support patients with
GHD.
Furthermore, constructing cost-effectiveness models
based on pertinent evidence regarding adult height,
other health outcomes, and quality of life may help in
confirming or revising current criteria although so far,
evidence based on long-term follow-up is limited [28,
32]. Previous work has calculated the incremental cost
effectiveness of GH treatment at approximately £6000
(about US $9000, using a 2002 exchange rate) per centi-
meter gained in adult height [33]. In addition to height,
we should also include metabolic effects [34, 35],
psychological effects [36–39], and short-term [40] and
long-term quality of life [41–44], all of which remain in-
conclusive and need further research.
This study has several limitations. First, the use of a
nonmandatory registry database could have caused a se-
lection bias. Although cases of discontinuation might be
less likely to be registered than those of continuation,
there is no reason to consider the registry to be affected
by the recipient status of financial support. Second, the
registry did not contain socio-economic information
about the patients. Future surveys should address the in-
fluence of these factors for in-depth understanding of
the process of patients’ decision-making. Third, some
patients may have been misclassified as eligible for local
subsidies. We determined the presence or absence of
local subsidies based on the locations of the treatment
providers, because the data set did not contain patients’
residences. Also, we did not account for differences in
benefits across municipalities, income-based eligibility
limit, or the presence of other subsidies, such as subsid-
ies for single parents or for the disabled [45]. However,
these factors would not have largely influenced our re-
sults. Any misclassification caused by substituting pa-
tients’ residences with locations of medical institutions
would have had a negligible effect on the results because
the eligibility criteria defined by neighboring municipal-
ities are usually similar under financial help by prefec-
tures [9]. The difference in benefits is relatively small
compared with the high cost of GH. Furthermore, mis-
classification of financial support eligibility criteria in
this study would likely result in the underestimation of
the relationship in two ways. Income-based eligibility
limit would prevent patients who otherwise satisfy cri-
teria from receiving support, making some patients who
appeared to be “eligible” for support more likely to have
discontinued therapy. Similarly, the presence of other
subsidies not considered in this study may have in-
creased the likelihood of patients continuing therapy
despite being categorized as “ineligible”.
Table 3 Sensitivity analyses of the odds ratio of financial support to continuing treatment
Boys Girls
OR 95 % CI OR 95 % CI
Base model (n = 620) 4.04 1.86–8.78 1.72 0.80–3.70
Excluding bone age (n = 696) 4.31 2.05–9.03 1.99 0.95–4.17
Including puberty status (n = 602) 4.11 1.88–8.96 1.76 0.81–3.80
Excluding patients not registered in the following year (n = 491) 2.91 1.21–6.97 2.37 0.99–5.67
CI confidence interval, OR odds ratio
Table 2 Multiple logistic regression analysis for factors related
to treatment decisions (n = 620)
Variables OR 95 % CI
Eligibility for financial supporta
Ineligible Reference
Eligible (girls) 1.72 0.80–3.70





Each additional year older 0.64 0.51–0.79
Height SDS
Each additional SDS increase 0.65 0.43–0.99
Growth velocity, cm/y
Each growth velocity increase 1.04 0.97–1.12
Bone age, yc
Each additional year older (girls) 0.69 0.52–0.93




When patients reached the height limit
Before October 2009 Reference
October 2009 and after 0.84 0.56–1.26
CI confidence interval, OR odds ratio
aEligibility for at least one of the national or local programs of financial
support after exceeding the height limit defined by the Medical Aid Program
for Chronic Pediatric Disease of Specified Categories
bComparing boys at the bone age of 15 y to girls at the bone age of 13 y, without
financial support (comparing different bone ages due to differential centering for
the variable)
cBone age was centered at 13 y in girls and at 15 y in boys
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Conclusions
This study revealed that financial support affects
decision-making for treatment of adolescents with GHD.
Because cost is a major consideration in GH treatment,
future cost-effectiveness analyses addressing quality-of-
life changes as well as physical and psychological im-
provement are needed to establish more evidence-based
criteria for public funding.
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